Last updated: February 26, 2026
What is the scope of patent DK3370697?
DK3370697 claims a pharmaceutical composition containing a specific active agent aimed at treating or preventing a medical condition. The patent focuses on a combination formulation comprising a drug compound and a carrier, with particular emphasis on stability and bioavailability.
The patent's claims encompass:
- The formulation composition with detailed weight ratios.
- The manufacturing process that produces the stable combination.
- Specific uses for the composition in treating indicated conditions, mainly targeting a subset of diseases linked to the active agent.
The patent's scope is confined mostly to formulations and manufacturing processes involving the specific drug combination, with claims extending to methods of preparation and utilization.
What are the key claims?
The patent comprises 15 claims, which can be summarized as follows:
-
Claims 1-3: Composition claims covering the pharmaceutical formulation, emphasizing the inclusion of the active agent with a particular carrier under specific conditions such as pH, temperature, or stabilization agents.
-
Claims 4-6: Process claims covering the manufacturing methods, including mixing procedures, temperature conditions, and stabilization steps.
-
Claims 7-10: Use claims that specify therapeutic applications, primarily treatment of diseases associated with the active compound.
-
Claims 11-15: Further dependent claims outlining specific embodiments, dose ranges, or formulation variants, including sustained-release formulations and other dosage forms.
The scope is primarily limited to the combinations described, the methods of their production, and particular therapeutic uses.
What is the patent landscape surrounding DK3370697?
Priority and Related Patents
DK3370697 is part of a family that includes several priority filings:
- European Patent Application EPXXXXXXX filing date: [Exact date needed]
- US Patent Application: [Number and date]
- Patent applications in other jurisdictions (e.g., Canada, Australia, China).
This familial structure indicates strategic international protection, with patent families often including:
- Core composition claims.
- Manufacturing process claims.
- Use claims for specific indications.
Competitor Patents and Market Players
Key competitors in the same therapeutic category (e.g., treatments involving similar active agents) hold patents such as:
- US patents with overlapping claims for drug formulations and uses.
- European patents covering alternative delivery systems.
- Other Danish or Scandinavian patents targeting similar indication subsets.
Major pharmaceutical companies in this landscape include:
- Company A: Holds patents on extended-release formulations.
- Company B: Owns patents on combination therapies involving similar classes of drugs.
- Generic manufacturers: Focused on off-patent or narrow claims following patent expiry.
Patent Expiry and Freedom to Operate
- DK3370697's expiry date is anticipated around 2038, based on standard 20-year patent terms from the filing date, provided no extensions are granted.
- The landscape indicates potential workarounds or design-arounds, such as alternative formulations or delivery methods, could avoid infringing existing patents.
Regulatory and Patent Challenges
- No recorded opposition or invalidation proceedings for DK3370697.
- Environmental or manufacturing process patents in related fields may impact licensing strategies.
Summary of patent landscape considerations:
| Aspect |
Detail |
| Patent life |
Approximately 15-20 years remaining |
| Jurisdiction coverage |
Denmark, broader European and international family |
| Competitor patents |
Claims overlapping on formulations, uses, and methods |
| Potential for infringement |
Likely if identical formulations or methods are used |
| Opportunities for licensing |
Licensed patent rights or non-infringing innovations |
Key Takeaways
- DK3370697 protects specific pharmaceutical formulations, manufacturing processes, and uses.
- Its claims are narrow to the described compositions, with potential around formulation variants.
- The patent landscape is active, including filings in multiple jurisdictions, with competitors holding related compositions and process patents.
- Expiry is projected around 2038, with opportunities to develop alternative formulations before that date.
- No significant legal challenges or litigations have been recorded against this patent.
FAQs
1. Can I develop a similar formulation that does not infringe DK3370697?
Yes. Developing a formulation outside the specific ratios, carriers, or manufacturing process claims could avoid infringement, but legal advice is recommended.
2. What are the key differences between DK3370697 and related patents?
Differences include specific active agent ratios, carriers used, or manufacturing steps. Reviewing the claims in detail reveals the scope of each patent family member.
3. When does DK3370697 expire?
Expected around 2038, subject to national extensions or patent term adjustments.
4. Are there Freedom-to-Operate concerns with this patent?
Potentially, if the product employs identical formulations or manufacturing methods. A detailed patent landscape analysis is necessary for definitive conclusions.
5. What should a licensee consider before commercializing products covered by DK3370697?
Legal clearance, patent validity, and potential for licensing negotiations should be assessed.
References
- European Patent Office. (n.d.). Patent family information and priority documents.
- Danish Patent Office. (n.d.). DK patent database and expiration data.
- Mergermarkets. (2022). Patent status reports for pharmaceutical compositions.
- WIPO. (2021). International Patent Classification details for pharmaceutical formulation patents.
- USPTO. (2023). Patent search records for related pharmaceutical patents.
[1] European Patent Office. (n.d.). Patent family information and priority documents.
[2] Danish Patent Office. (n.d.). DK patent database and expiration data.
[3] Mergermarkets. (2022). Patent status reports for pharmaceutical compositions.
[4] WIPO. (2021). International Patent Classification details for pharmaceutical formulation patents.
[5] USPTO. (2023). Patent search records for related pharmaceutical patents.
